Treatment With pMDI Ensifentrine Found to Improve Lung Function

Treatment With pMDI Ensifentrine Found to Improve Lung Function

309526

Treatment With pMDI Ensifentrine Found to Improve Lung Function

Seven days of treatment with ensifentrine, given using a pressurized metered-dose inhaler — called a pMDI — resulted in marked lung function improvements in people with moderate to severe chronic obstructive pulmonary disease (COPD), according to data from a Phase 2 clinical trial. “This study demonstrates that ensifentrine administered by hand-held pMDI over one week provides clinically meaningful, statistically significant and dose-dependent bronchodilation,” researchers from Verona Pharma, the company developing ensifentrine, wrote in the study…

You must be logged in to read/download the full post.